Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSB205 in advanced solid tumors
NCT03986606Phase 1Unknown
- Sponsor
- Qilu Puget Sound Biotherapeutics
- Start
- Jul 2019
- Primary completion
- Feb 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QL1706 in solid tumor (advanced stage), sponsored by Qilu Puget Sound Biotherapeutics. Primary endpoints: Safety and tolerability at 28 days, Maximum Tolerated Dose and 1 more. Status: unknown.
02
Drugs
QL1706
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03986606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03986606.